Kratak sadr`aj: Dijabetes predstavlja ~est metaboli~ki poreme}aj, ~ije mikrovaskularne i makrovaskularne komplikacije doprinose smrti, invaliditetu i skra}enju o~e kivanog `ivotnog veka kod obolelih. Ova bolest podrazumeva velike tro{kove a pored pacijenta i njegove porodice poga|a i javno zdravlje, zajednice i dru{tvo. Dijabetes zahteva sve ve}i deo nacionalnih tro{kova zdravstva. Prevencija razvoja dijabetesa i njegovih komplikacija je va`an problem. U cilju razumevanja mehanizama razvoja i progresije komplikacija u dijabetesu vr{i se istra`ivanje biomarkera. U ovom radu dat je pregled biomarkera koji se preporu~uju u klini~koj praksi i pravilnicima za laboratorijsku medicinu i koji su istra`ivani radi predikcije ili dijagnostikovanja kom plikacija u dijabetesu. U sa`etom obliku su prikazani rezultati nekoliko klini~kih studija.
Introduction
Diabetes mellitus is a complex metabolic disorder and one of the main chronic diseases worldwide. The number of people with diabetes is estimated at 285 million in 2010, and it is expected to be over 438 million by the year 2030 (1) . Close to four million deaths in the 20-79 age group may be attributable to diabetes in 2010, accounting for 6.8% of the global all-cause morta lity in this age group (2) . Besides the impact on the pa tients' quality of life, the microvascular (dia betic re tinopathy-DR, nephropathy-DN, neuro pathy) and ma cro vascular complications (coronary heart di seases, peri pheral artery diseases, and stroke) of diabetes also increase the national health care expenditure. Estimated global health care expenditures to treat and prevent diabetes and its complications are expected to total at least 376 billion US Dollars (USD) in 2010. By 2030, this number is projected to exceed some 490 billion USD (3) . Globally, diabetes is likely to be the fifth leading cause of death (4) .
Prevention of diabetes and its complications, early detection of disease stages, and therapeutics that would act in the presence of hyperglycemia to prevent, delay or reverse the complications are the major concerns. Biomarkers are studied for under standing the mechanisms of hyperglycemia-caused metabolic abnor malities (5, 6) such as polyol pathway activation, non-enzymatic glycosylation/Maillard reac tion, activation of protein kinase C (PKC), altered gene expression, and growth factor activation. These include bio markers of inflammation (7, 8) , advanced glycation (9-12), endothelial dysfunction, oxidative stress and anti oxi dant mechanisms (10, 11, (13) (14) (15) , hemostasis/thrombosis, cellular adhesion molecules, mitochondrial dysfunction, and the activation in the PKC signaling pathway, lipid status (8) , and microangiopathies that cause organ damage (9, (16) (17) (18) (19) .
Besides the standard laboratory techniques, advan ced technologies such as genomics, proteomics (20) (21) (22) (23) (24) (25) (26) , metabolomics (27) , transcriptomics (28) , lipidomics (29) (30) (31) and glycomics (32) have been used to identify biomarkers.
Although uncontrolled hyperglycemia-related tissue damage is the primary cause of diabetic complications, the course of complications may be altered by genetic and environmental factors, and therefore the complications are not developed to the same degree in all patients. In this context, the genetic basis of diabetes complications is also being inves tigated (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) .
The pathogenesis of diabetes complications is complex and multifactorial, has extensive implications, and leads to multiorgan failure. There is an established heterogeneity in the determinants of the risk of dia betes complications. The heterogeneity leads to consideration of the personalized approach to diagnostic and treatment strategies of diabetes and its complications (43) (44) (45) . The spectrum of information that can guide persona lized decisions on diabetes care also includes individual behavioral and clinical phenotypic features, standard clinical laboratory findings, and gene sequ ences and other molecular markers. All techni ques have been used for the identification of bio markers.
We should also keep in mind that the occurrence and progress of diabetes complications is not influenced only by hyperglycemia and related metabolic abnormalities, but also by the presence of nonglycemic risk factors such as hypertension, dyslipidemia (46) , as well as age, duration of diabetes, and obesity.
Biomarkers recommended for management of diabetes and prevention of its complications
The biomarkers related to laboratory measu rements, and recommended for the assessment of dia betes complications are summarized in Table I . As seen in • Urinary albumin excretion rate and uAlb:creat ratio • eGFR (Cockroft-Gault and MDRD) • TGF-beta in urine -Microalbuminuria is a key predictor for the development of CKD in people with type 2 diabetes, however CKD may develop in the absence of abnormalities in albumin excretion (Level IIPrognosis). -AER and ACR are the most common and reliable methods to assess albuminuria based on sensitivity and specificity, however both methods are subject to high intra-individual variability so that repeated tests are needed to confirm the diag nosis (Level III -Diagnostic Accuracy). -Estimation of GFR (eGFR) ba sed on serum creatinine is a pragmatic, clinically relevant appro ach to assessing kidney func tion in people with type 2 dia betes (Level III -Diagnostic Accuracy). Table I , the recommended biomarkers for assessing the complications of diabetes are few, and yet none of them is relevant for the prediction and diagnosis of diabetes complications.
Although HbA1c is a good marker for the determi nation of mean glycaemia, and microalbuminuria is considered to be a predictor of cardiovascular dis ease, and if it increases gradually to macroalbuminuria, microalbuminuria is also associated with end-sta ge renal disease, it is currently impossible to reliably predict when and which diabetic patients will develop retinopathy, nephropathy or neuropathy. Biomarkers are urgently needed for the early pre-clinical stages through the late organ failure stages of diabetes complications.
Molecules investigated for determination of progression, prediction and/or diagnosis of diabetic complications
As seen in Table II , there are lots of molecules that are associated with the metabolic abnormalities which are caused by hyperglycemia and have been studied for the prediction and/or diagnosis of diabetes complications.
Matheson et al. (19) reviewed urinary bio markers that may be used to monitor the development and progression of diabetes and its complications. Their conclusion is that biomarkers of renal dysfunction (such as transferrin, type IV collagen and N-acetyl-b-Dglucosaminidase) may prove to be more sensitive than urinary albumin in the detection of incipient nephropathy and risk assessment of cardiovascular disease. Inflammatory markers including orosomucoid, tumour necrosis factor-b, transforming growth factor-b, vascular endothelial growth factor and monocyte chemo attractant protein-1, as well as oxidative stress markers such as 8-hydroxy-2 deoxyguanosine may also be useful biomarkers for the diagnosis or monitoring of diabetic complications, particularly kidney disease. 
Urinary proteins (or their fragments) found associated with renal damage in the context of diabetes, and discovered by proteomic approaches (e.g. 2D-GE and MALDI-MS/MS) or by profiling methods (e.g. SELDI-TOF-MS).
Downregulated proteins: a1-microglobulin/bikunin precursor (AMBP), apolipoprotein A-I, apolipoprotein CIII, apolipoprotein E, collagen a-6 (IV), collagen a-1 (IV), collagen a-1 (V), collagen a-1 (I), collagen a-1 (III), collagen a-2 (I), complement component C4 A, complement factor H-related 1, complement factor I light chain, C-type lectin domain family 3 member B, ficolin 3 precursor, glutathione peroxidase precursor, haptoglobin precursor, haptoglobin-related protein precursor, hemopexin precursor, histidine-rich glycoprotein, kallikrein-3, MASP-2-related protein, proapo-A-I protein, prostatic acid phosphatase precursor, relaxin-like factor INSL3, fragment, retinol-binding protein, retinol-binding protein 4, ribonuclease 2, sex hormonebinding globulin, transthyretin precursor, tenascin-X, UbA52, uromodulin, fragment, pigment epithelium-derived factor; Upregulated proteins: adiponectin precursor, albumin, fragment of, a-1-antitrypsin, a2-HS-glycoprotein precursor (fetuin A), b2-microglobulin, b-2-glycoprotein 1, calgranulin B, carbonic anhydrase 1, collagen a-1 (II), collagen a-1(I), collagen a-5(IV), complement component C4A, complement component C4B3, complement factor H-related 1, complex-forming glycoprotein HC, cubilin, epithelial-cadherin precursor, FAT tumour suppressor, hemopexin, Ig heavy chain, Ig k chain C region, Ig k chain V-II region cum, Ig k chain V-III region SIE, inositol pentakisphosphate 2-kinase, kininogen precursor, megalin, orosomucoid (1-acid glycoprotein), pigment epithelium-derived factor, prostaglandin-H2-isomerase precursor, prostaglandin-H2-isomerase precursor, retinol-binding protein precursor, transthyretin precursor, vitamin D-binding protein, zinc-a2-glycoprotein 1; Proteins without assessment of up or downregulation: a-1-antitrypsin, a-1-microglobulin, albumin, complement factor B, haptoglobin, hemopexin, orosomucoid, plasma retinol binding, transferrin, transthyretin, zinc a-2-macroglobulin (49, 26) .
Genes: aldose reductase, vascular endothelial growth factor, angiotensin-I converting enzyme (50); SOD2 (51) .
The other biomarkers that have been investigated: urinary 8-hydroxydeoxyguanosine (8-OHdG) (52) , osteoprotegerin (53) , hepatocyte growth factor (HGF) (54, 55) , matrix metalloproteinase-9 (MMP-9) (56), cystatin C (57), 1,5 anhydroglucitol (58, 59), neutrophil gelatinase-associated lipocaline (NGAL) (60) , , HbA1c, fructosamine, glycated albumin (62) .
retin, alpha-1 microglobulin/bikunin precur sor, and haptoglobin precursors as downregulated urinary prot eins, and albumin, zinc alpha-2 glycoprotein, retinal binding proteins and E-cadherin as upregulated urinary proteins in type 2 diabetics, by using proteomic analysis.
The candidate genes involved in the pathways which are dysregulated in diabetes leading to complications have been treated as potential candidate ge nes for DR. Among approximately 14 genes, only three (aldose reductase -AKR1B1, vascular endothelial growth factor -VEGF, angiotensin-I con verting enzyme -ACE) were found to be associated with DR (50) . The metaanalysis performed by Tian et al. (51) suggested that the C allele of C47T polymorphism in SOD2 gene has protective effects on diabetic microvascular complications, diabetic nephropathy, and diabetic retinopathy.
Conclusion
As emphasized in this paper, almost all meta bolites, products, genes and molecules that are involved in the metabolic abnormalities related to uncontrolled hyperglycemia are candidate biomarkers. The other micro-and macrovascular risk factors for organ damages should also be considered in the assessments. The personalized nature of diabetes and its complications is another challenging issue, since genetic and environ mental factors interact in complex ways. In spite of the findings from the researches and even the recommen dations in the guidelines, there is still a gap between the levels of target values of biomarkers to reduce complications and the levels of these targets achieved in actual medical practice. Within the con text of these realities, the translational research projects may be helpful for collecting real life data from the managed health care of diabetic patients, besides the bench side researches mentioned above. To accomplish this, the scientific and clinical societies and also the stakeholders in the area of diabetes research and care should work in a collaborative manner in a wide spectrum of disciplines. This may close the gap between the biomarker levels targeted or recommended and the levels achieved in real life, and also provide more relevant biomarkers for the detection of progression and early stages of complications.
In the translational research context, the clinical laboratory may play a significant central role with a properly structured laboratory information system and also data mining tools.
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